

Community Drug Checking Network
Project Site Scope of Work
Year 1 October 1, 2022 – June 30, 2023

The Addictions, Drug & Alcohol Institute (ADAI) at the University of WA has been funded by the WA State Health Care Authority to develop, implement, and evaluate a Community Drug Checking Network (CDCN) in WA State. The goal of this network is to document details about the illicit drug supply in Washington State to inform actions of individuals, harm reduction programs, community providers, and public health entities to prevent overdose deaths.

Drug checking best practice combines use of both Fourier-transform infrared spectroscopy (FTIR) and fentanyl test strips to allow for fast, real-time qualitative analysis of drugs for the presence of fentanyl, other drugs, adulterants, and contaminants. After point-of-care results are given to participants, samples will be sent for confirmatory testing at a toxicology laboratory. Confirmed results will be aggregated and disseminated on a website developed by ADAI in collaboration with participating sites and people with lived/living experience. Input and ideas from program participants will be actively solicited and integrated into all phases of project planning, implementation, and evaluation.

Project term: (Year 1: October 1, 2022 – June 30, 2023; Year 2: July 1, 2023 – June 30, 2024)

As part of the Community Drug Checking Network, each contracted organization will:

1. In collaboration with ADAI, establish and maintain comprehensive drug checking services (DCS) and ensure that DCS are integrated within existing harm reduction services.
2. Hire a Drug Checking Technician (DCT) to conduct drug testing and coordinate project activities at the site(s) and in collaboration with ADAI and other CDCN contracted organizations. The DCT will also facilitate ongoing dialog and input from people who use drugs and other community stakeholders. Contracted organizations will ensure the DCT participates in all online and in-person trainings coordinated by ADAI. Contracted organizations may, upon approval of ADAI, add other relevant trainings to the DCT's required training list.
3. Develop and implement a process to solicit and incorporate participant input into the design, implementation, information dissemination, and evaluation of DCS.
4. Adhere to comprehensive guidelines and protocols (to be to:
 - Promote and communicate with program participants about the availability of drug checking services.
 - Properly receive drug samples from participants, test samples with the FTIR machine, analyze results, and communicate those results to the participants.
 - Perform auxiliary testing with fentanyl and/or benzodiazepine test strips, as indicated in guidelines.
 - Follow talking points when communicating results and harm reduction messages to participants.
 - Return tested materials to participants.
 - Package and ship a designated percentage of samples to a laboratory for confirmatory testing.
 - Keep FTIR machine and all supplies in locked areas when not in use.
 - Maintain cleanliness of testing area and FTIR machine and properly dispose of all testing materials.
5. Use project templates and databases to collect, compile, and submit to ADAI data on:
 - Participant demographics (to be determined)
 - Test sample characteristics (e.g., appearance, sold as, prior experiences with drug)
 - FTIR and fentanyl test strip results
 - Test samples sent for confirmatory testing and results of testing

6. Conduct anonymous surveys (developed with ADAI and CDCN sites) with 10 participants each quarter about their experiences using the DCS.
7. In January 2023 and February 2023, test a minimum of 40 samples (20 samples per month x 2 months) and send 100 percent of samples for confirmatory testing.
8. Between March 2023 and June 2023, test a minimum of 240 samples (60 samples per month x 4 months) and send 20 percent of samples for confirmatory testing.
9. Participate in trainings, technical assistance meetings, and coordination with CDCN sites and ADAI.
10. Meet monthly with ADAI and CDCN sites to discuss project implementation and problem-solving.
11. Document and submit a Monthly Report to ADAI on the following items:
 - Number of individuals using DCS.
 - Number and characteristics of samples tested per site at each contracted organization and preliminary results.
 - Number of samples sent for confirmatory testing and results (lagged turnaround).
 - Summary of barriers encountered and efforts to overcome the barrier(s).
12. Coordinate with ADAI on other related data gathering and dissemination activities as mutually agreed upon.

YEAR 1 BUDGET = \$80,696

SFY2023 Deliverables (10/1/22-6/30/23)	Due Date	Payment
1. Hire a Drug Checking Technician (DCT)	November 30, 2022	\$1,000
2. Complete required DCT training	January 15, 2023	\$2,000
3. Test at least 20 samples per month in January and February 2023. (40 samples minimum)	Last day of each month	\$200/sample x 20 samples x 2 mo = \$8,000max
4. Test at least 60 samples per month from March through June 2023. (240 samples minimum)	Last day of each month	\$200/sample x 60 samples x 4 mo = \$48,000 max
5. Benchmark for testing 280 total samples	June 30, 2023	\$696
6. Conduct 10 participant surveys each quarter	December 30, 2022 March 30, 2023 June 30, 2023	\$1,000/quarter x 3 qrtrs = \$3,000
7. Submit monthly report	10 th of the following month	\$1,000/month x 9 months = \$9,000 max
8. Meet monthly with CDCN project team	Monthly	\$1,000/month x 9 months = \$9,000 max